Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Utilizing the estrogen receptor ligand-binding domain for controlled protein translocation to the insoluble fraction.

Davis JR, Mossalam M, Lim CS.

Pharm Res. 2012 Dec;29(12):3455-63. doi: 10.1007/s11095-012-0840-3. Epub 2012 Aug 7.

2.

Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.

Long X, Fan M, Nephew KP.

Cancer Biol Ther. 2010 Mar 1;9(5):389-96. Epub 2010 Mar 11.

PMID:
20061804
3.
4.

Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant.

Evers NM, Wang S, van den Berg JH, Houtman R, Melchers D, de Haan LH, Ederveen AG, Groten JP, Rietjens IM.

Chem Biol Interact. 2014 Sep 5;220:222-30. doi: 10.1016/j.cbi.2014.06.019. Epub 2014 Jul 8.

PMID:
25014417
5.

Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.

Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK, Lee AV.

Mol Endocrinol. 2000 Mar;14(3):369-81.

PMID:
10707955
6.

Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.

Dixon AS, Constance JE, Tanaka T, Rabbitts TH, Lim CS.

Pharm Res. 2012 Apr;29(4):1098-109. doi: 10.1007/s11095-011-0654-8. Epub 2011 Dec 20.

7.

Cooperative coactivation of estrogen receptor alpha in ZR-75 human breast cancer cells by SNURF and TATA-binding protein.

Saville B, Poukka H, Wormke M, Janne OA, Palvimo JJ, Stoner M, Samudio I, Safe S.

J Biol Chem. 2002 Jan 25;277(4):2485-97. Epub 2001 Nov 5.

8.

Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor.

Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, Wang Z.

J Biol Chem. 2003 Oct 24;278(43):41998-2005. Epub 2003 Aug 15.

9.

Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.

Long X, Fan M, Bigsby RM, Nephew KP.

Mol Cancer Ther. 2008 Jul;7(7):2096-108. doi: 10.1158/1535-7163.MCT-07-2350.

10.
11.

Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells.

El Khissiin A, Journé F, Laïos I, Seo HS, Leclercq G.

Steroids. 2000 Dec;65(12):903-13.

PMID:
11077089
12.

Optimizing the protein switch: altering nuclear import and export signals, and ligand binding domain.

Kakar M, Davis JR, Kern SE, Lim CS.

J Control Release. 2007 Jul 31;120(3):220-32. Epub 2007 May 3.

13.
14.

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.

Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, Knowlden JM, Nicholson RI, Gee JM.

Breast Cancer Res. 2011 Mar 11;13(2):R29. doi: 10.1186/bcr2848.

15.

Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation.

Zhao C, Koide A, Abrams J, Deighton-Collins S, Martinez A, Schwartz JA, Koide S, Skafar DF.

J Biol Chem. 2003 Jul 18;278(29):27278-86. Epub 2003 May 6.

18.

Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization.

Chen D, Pace PE, Coombes RC, Ali S.

Mol Cell Biol. 1999 Feb;19(2):1002-15.

20.

Supplemental Content

Support Center